Abstracts Archive - Page 680 of 2425 - ACR Meeting Abstracts

Abstract Number: 0787 • ACR Convergence 2020
MerTK Synovial Expression Correlates with Disease Activity and Treatment Response in Rheumatoid Arthritis Patients
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Giulia Maria Ghirardi², Gloria Lliso-Ribera², Felice Rivellese¹, Myles Lewis¹, Michele Bombardieri², Frances Humby² and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: Despite valuable improvements in long-term clinical outcomes, a significant portion of rheumatoid arthritis (RA) patients still do not adequately respond to available treatments, and…
Abstract Number: 0786 • ACR Convergence 2020
A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA)
Christian Geier¹, Jon Giles¹, Samantha Gaines², Christopher Depender¹, Joan Bathon¹ and Robert Winchester¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: The presentation of MHC-peptide complexes to T lymphocytes via antigen-presenting cells (APC) is a crucial step in the initiation of immune responses. Dendritic cells…
Abstract Number: 0792 • ACR Convergence 2020
LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis
Xuechan Huang¹, Tianwang Li¹, Shuyang Chen¹, Zhixiang Huang¹ and Junming Chen¹, ¹Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangdong, China (People's Republic)
Background/Purpose: Neutrophils play a central role in host defense, but they also play important effectors on acute and chronic inflammation. Neutrophil apoptosis is essential for…
Abstract Number: 0791 • ACR Convergence 2020
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari¹, Takeo Isozaki¹, Kuninobu Wakabayashi¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
Abstract Number: 0797 • ACR Convergence 2020
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Adela Castro¹, Jesus Diaz² and Guillermo Quiceno³, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Janus Kinase (JAK) inhibitors have shown long term benefit in patients with active RA with inadequate response to conventional or biologic DMARDs (1). Due to…
Abstract Number: 0799 • ACR Convergence 2020
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
Renske Hebing¹, Wouter Bos¹, Mike Nurmohamed² and Bart van den Bemt³, ¹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
Abstract Number: 0794 • ACR Convergence 2020
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
Aina Teniente-Serra¹, Lourdes Mateo², Agueda Prior³, Monica Guma⁴, Eva Martinez-Caceres¹ and Melania Martinez-Morillo⁵, ¹Department of Immunology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain
Background/Purpose: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets…
Abstract Number: 0789 • ACR Convergence 2020
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Xiarepati Tieliwaerdi¹, Nozima Aripova¹, Michael Duryee¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
Abstract Number: 0802 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Yoshiya Tanaka¹, Hisashi Yamanaka², Leslie Harrold³, Tin-chi Lin³, Ekta Agarwal⁴, Jose L Rivas⁵, Naonobu Sugiyama⁶, Jeffrey Greenberg⁷ and Mitsumasa Kishimoto⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ³Corrona, LLC, Waltham, MA, ⁴Pfizer, Inc., Princeton Jct, NJ, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Japan Inc, Tokyo, Japan, ⁷Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁸Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…
Abstract Number: 0806 • ACR Convergence 2020
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Anthony Cordisco¹ and Joshua Baker¹, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 0809 • ACR Convergence 2020
Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study
Sergio Schwartzman¹, Shelly Kafka², Douglas Conaway³, Aaron Broadwell⁴, Shawn Black², Stephen Xu⁵, Wayne Langholff⁶ and Jeffrey R Curtis⁷, ¹Weill Cornell Medical College, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Grand Strand Regional Medical Center, Myrtle Beach, SC, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁵Janssen Research & Development, LLC, Spring House, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is a Phase 4, prospective, noninterventional, observational, multicenter (88 sites), 3-year…
Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Elise van Mulligen¹, Saad Ahmed¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
Abstract Number: 0696 • ACR Convergence 2020
Femoral Cartilage Ultrasound Echo-Intensity Associates with Arthroscopic Cartilage Damage in People Following Anterior Cruciate Ligament Reconstruction
Matthew Harkey¹, Erin Little², Mikaela Thompson³, Ming Zhang⁴, Jeffrey Driban⁴ and Matthew Salzler³, ¹University of Massachusetts, Worcester, MA, ²Tufts Medical Center, Cambridge, MA, ³Tufts Medical Center, Boston, ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Over one-third of people will develop knee osteoarthritis within 10 years of an anterior cruciate ligament (ACL) injury. Ultrasound may be used to monitor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].